Literature DB >> 28953106

Levosimendan in Advanced Heart Failure: Where Do We Stand?

Antonio Abbate1, Benjamin W Van Tassell2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 28953106      PMCID： PMC5839945          DOI： 10.1097/FJC.0000000000000539

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN： 0160-2446            Impact factor:   3.105


× No keyword cloud information.
  6 in total

1.  Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery.

Authors:  Rajendra H Mehta; Jeffrey D Leimberger; Sean van Diepen; James Meza; Alice Wang; Rachael Jankowich; Robert W Harrison; Douglas Hay; Stephen Fremes; Andra Duncan; Edward G Soltesz; John Luber; Soon Park; Michael Argenziano; Edward Murphy; Randy Marcel; Dimitri Kalavrouziotis; Dave Nagpal; John Bozinovski; Wolfgang Toller; Matthias Heringlake; Shaun G Goodman; Jerrold H Levy; Robert A Harrington; Kevin J Anstrom; John H Alexander
Journal:  N Engl J Med       Date:  2017-03-19       Impact factor: 91.245

2.  Reverse left ventricular remodeling by intermittent dobutamine infusions and amiodarone in end-stage heart failure due to idiopathic dilated cardiomyopathy.

Authors:  John N Nanas; Eleftheria P Tsagalou; Serafim N Nanas; John V Terrovitis; Elias J Tsolakis; Savas Toumanidis; Panagiotis D Papazoglou; George P Alexopoulos; John Kanakakis; Maria I Anastasiou-Nana
Journal:  Int J Cardiol       Date:  2005-09-22       Impact factor: 4.164

3.  Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial.

Authors:  Johann Altenberger; John T Parissis; Angelika Costard-Jaeckle; Andreas Winter; Christian Ebner; Apostolos Karavidas; Kurt Sihorsch; Ekaterini Avgeropoulou; Thomas Weber; Lida Dimopoulos; Hanno Ulmer; Gerhard Poelzl
Journal:  Eur J Heart Fail       Date:  2014-06-11       Impact factor: 15.534

Review 4.  Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies.

Authors:  Giovanni Landoni; Giuseppe Biondi-Zoccai; Massimiliano Greco; Teresa Greco; Elena Bignami; Andrea Morelli; Fabio Guarracino; Alberto Zangrillo
Journal:  Crit Care Med       Date:  2012-02       Impact factor: 7.598

5.  Levosimendan for Hemodynamic Support after Cardiac Surgery.

Authors:  Giovanni Landoni; Vladimir V Lomivorotov; Gabriele Alvaro; Rosetta Lobreglio; Antonio Pisano; Fabio Guarracino; Maria G Calabrò; Evgeny V Grigoryev; Valery V Likhvantsev; Marcello F Salgado-Filho; Alessandro Bianchi; Vadim V Pasyuga; Massimo Baiocchi; Federico Pappalardo; Fabrizio Monaco; Vladimir A Boboshko; Marat N Abubakirov; Bruno Amantea; Rosalba Lembo; Luca Brazzi; Luigi Verniero; Pietro Bertini; Anna M Scandroglio; Tiziana Bove; Alessandro Belletti; Maria G Michienzi; Dmitriy L Shukevich; Tatiana S Zabelina; Rinaldo Bellomo; Alberto Zangrillo
Journal:  N Engl J Med       Date:  2017-03-21       Impact factor: 91.245

Review 6.  Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications.

Authors:  Johann Altenberger; Finn Gustafsson; Veli-Pekka Harjola; Kristjan Karason; Detlef Kindgen-Milles; Matti Kivikko; Gabriella Malfatto; Zoltán Papp; John Parissis; Piero Pollesello; Gerhard Pölzl; Carsten Tschöpe
Journal:  J Cardiovasc Pharmacol       Date:  2018-03       Impact factor: 3.105
  6 in total
  1 in total

Review 1.  Biophysical Derangements in Genetic Cardiomyopathies.

Authors:  Melissa L Lynn; Sarah J Lehman; Jil C Tardiff
Journal:  Heart Fail Clin       Date:  2018-04       Impact factor: 3.179
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.